Acuitas Investments’s Harvard Bioscience HBIO Stock Holding History

Acuitas Investments’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-49,109	Closed	-$215K	–	19
2025 Q3	$215K	Hold	49,109	–	–	0.14%	44
2025 Q2	$218K	Hold	49,109	–	–	0.17%	49
2025 Q1	$278K	Hold	49,109	–	–	0.24%	54
2024 Q4	$1.04M	Hold	49,109	–	–	0.85%	43
2024 Q3	$1.32M	Buy	49,109 +8,375	+21%	+$247K	0.59%	67
2024 Q2	$1.16M	Buy	40,734 +8,082	+25%	+$283K	0.62%	63
2024 Q1	$1.38M	Hold	32,652	–	–	0.7%	55
2023 Q4	$1.75M	Buy	32,652 +8,474	+35%	+$383K	0.91%	47
2023 Q3	$1.04M	Buy	24,178 +6,148	+34%	+$284K	0.61%	59
2023 Q2	$990K	Buy	+18,030	New	+$989K	0.58%	62
2022 Q1	–	Sell	-43,245	Closed	-$3.05M	–	46
2021 Q4	$3.05M	Buy	43,245 +5,661	+15%	+$403K	1.3%	38
2021 Q3	$2.62M	Buy	37,584 +4,935	+15%	+$393K	1.15%	44
2021 Q2	$2.72M	Buy	32,649 +12,649	+63%	+$895K	1.36%	36
2021 Q1	$1.09M	Buy	+20,000	New	+$973K	0.63%	65

Other funds holding HBIO

WCM

Weber Capital Management San Francisco, California $100M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

MIM

Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return

CCM

Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM

Acuitas Investments's HBIO Position: Q4 2025 in Review

Acuitas Investments sold out of Harvard Bioscience (HBIO) in Q4 2025, closing a stake of 49,109 shares — an estimated $215K sold.

Acuitas Investments first reported a position in HBIO in Q1 2021 and held it in 14 quarters. The position peaked at $3.05M in Q4 2021. 63 funds tracked by Wall St. Rank hold HBIO as of Q4 2025.

Acuitas Investments reported no remaining Harvard Bioscience position as of Q4 2025 after selling out during the quarter.
Acuitas Investments sold 49,109 Harvard Bioscience shares in Q4 2025, an estimated $215K.
Acuitas Investments first reported a position in Harvard Bioscience in Q1 2021 and held it in 14 quarters.
Acuitas Investments's Harvard Bioscience position peaked at $3.05M in Q4 2021.
63 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2025.

Based on Acuitas Investments's 13F filing for Q4 2025, filed 27 Jan 2026.